The report covers the top 10 life sciences trends projected for 2025, highlighting key areas of innovation and growth in the industry. It explores how obesity treatment breakthroughs and antibody-drug conjugates (ADCs) are poised to disrupt the market, with the ADC market alone expected to reach $40 billion by 2030. Additionally, cell and gene therapies will see rapid advancements, while biosimilars are set for significant growth, driven by patent expirations and favorable regulatory conditions. Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) models will reshape healthcare access and personalization. The report also emphasizes the role of AI, forecasted to add up to $410 Bn annually through improvements in drug development, clinical trials, and precision medicine. Furthermore, it covers how pharmaceutical companies are transitioning to value-based healthcare models (Commercialization 3.0), the reshaping of launch strategies, and the expected rise in M&A activities. Real-World Evidence (RWE) integration will become a critical tool for pharma companies, driving better decision-making and unlocking significant value throughout the product lifecycle.
